Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;564(7736):439-443.
doi: 10.1038/s41586-018-0705-y. Epub 2018 Nov 7.

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M Ramanjulu  1 , G Scott Pesiridis  2 , Jingsong Yang  3 , Nestor Concha  4 , Robert Singhaus  2 , Shu-Yun Zhang  3 , Jean-Luc Tran  2 , Patrick Moore  2 , Stephanie Lehmann  5 , H Christian Eberl  5 , Marcel Muelbaier  5 , Jessica L Schneck  4 , Jim Clemens  4 , Michael Adam  3 , John Mehlmann  2 , Joseph Romano  2 , Angel Morales  2 , James Kang  2 , Lara Leister  2 , Todd L Graybill  2 , Adam K Charnley  2 , Guosen Ye  4 , Neysa Nevins  4 , Kamelia Behnia  2 , Amaya I Wolf  2 , Viera Kasparcova  2 , Kelvin Nurse  4 , Liping Wang  4 , Ana C Puhl  4 , Yue Li  4 , Michael Klein  4 , Christopher B Hopson  3 , Jeffrey Guss  4 , Marcus Bantscheff  5 , Giovanna Bergamini  5 , Michael A Reilly  2 , Yiqian Lian  3 , Kevin J Duffy  3 , Jerry Adams  3 , Kevin P Foley  2 , Peter J Gough  2 , Robert W Marquis  2 , James Smothers  3 , Axel Hoos  3 , John Bertin  2
Affiliations

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M Ramanjulu et al. Nature. 2018 Dec.

Erratum in

  • Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.
    Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J. Ramanjulu JM, et al. Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5. Nature. 2019. PMID: 31142845

Abstract

Stimulator of interferon genes (STING) is a receptor in the endoplasmic reticulum that propagates innate immune sensing of cytosolic pathogen-derived and self DNA1. The development of compounds that modulate STING has recently been the focus of intense research for the treatment of cancer and infectious diseases and as vaccine adjuvants2. To our knowledge, current efforts are focused on the development of modified cyclic dinucleotides that mimic the endogenous STING ligand cGAMP; these have progressed into clinical trials in patients with solid accessible tumours amenable to intratumoral delivery3. Here we report the discovery of a small molecule STING agonist that is not a cyclic dinucleotide and is systemically efficacious for treating tumours in mice. We developed a linking strategy to synergize the effect of two symmetry-related amidobenzimidazole (ABZI)-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function. Intravenous administration of a diABZI STING agonist to immunocompetent mice with established syngeneic colon tumours elicited strong anti-tumour activity, with complete and lasting regression of tumours. Our findings represent a milestone in the rapidly growing field of immune-modifying cancer therapies.

PubMed Disclaimer

Comment in